UK ITP Treatment Update: Quentin Hill on Generic Eltrombopag Access and Guidance
Quentin Hill, Consultant Haematologist at Leeds Teaching Hospitals NHS Trust, has shared a post on LinkedIn:
“From October 2025, the UK will have access to generic eltrombopag.
Eltrombopag is one of three thrombopoietin receptor agonists (TPO RA) that are licensed treatments for immune thrombocytopenia (ITP).
While these treatments are not identical, their effectiveness is broadly similar, and greater use of generic eltrombopag will result in a substantial, multi-million-pound cost saving to the NHS.
In a joint position statement, the UK ITP Forum and UK ITP Support Association have recommended generic eltrombopag as the preferred initial TPO RA for use second line in ITP.
However, patients currently stabilised/established on a different TPO RA should continue with their treatment, and access to alternative NICE approved TPO RA (romiplostim, avatrombopag) should continue.”
You can find more information here.
Find more posts on Hemostasis Today.
-
Apr 6, 2026, 16:21Anand Padmanabhan: A New Concise Nutshell Review of MGTS as an Emerging Thrombophilia
-
Apr 6, 2026, 16:20Satyam Arora: Why Are We Transfusing Kids in India?
-
Apr 6, 2026, 16:17Jim Hoffman: Extracorporeal Blood Purification as an Alternative to IVIG and Transfusion in Autoimmune Disease
-
Apr 6, 2026, 16:16Ala Eddin Sagar: What Changed in the New Sepsis Guidelines 2026
-
Apr 6, 2026, 16:13Simon Senanu: Hypersegmented Neutrophils – A Classic Sign of Megaloblastic Anemia
-
Apr 6, 2026, 16:05Peter Bou Dib: Understanding von Willebrand Factor in Bleeding and Thrombotic Disorders
-
Apr 6, 2026, 15:30Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 3
-
Apr 6, 2026, 15:19Ifeanyichukwu Ifechidere: When PT and APTT Are Normal but Bleeding Persists
-
Apr 6, 2026, 14:59Michal Farkowski: Cardiooncology Also Deals with Arrhythmia